|
1
|
Padala SA and Barsouk A, Thandra KC,
Saginala K, Mohammed A, Vakiti A, Rawla P and Barsouk A:
Epidemiology of renal cell carcinoma. World J Oncol. 11:79–87.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bukavina L, Bensalah K, Bray F, Carlo M,
Challacombe B, Karam JA, Kassouf W, Mitchell T, Montironi R and
O'Brien T: Epidemiology of renal cell carcinoma: 2022 update. Eur
Urol. 82:529–542. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Musaddaq B, Musaddaq T, Gupta A, Ilyas S
and von Stempel C: Renal cell carcinoma: The evolving role of
imaging in the 21st century. Semin Ultrasound CT MR. 41:344–350.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scosyrev E, Messing EM, Sylvester R and
Van Poppel H: Exploratory subgroup analyses of renal function and
overall survival in european organization for research and
treatment of cancer randomized trial of Nephron-sparing surgery
versus radical nephrectomy. Eur Urol Focus. 3:599–605. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goswami PR, Singh G, Patel T and Dave R:
The WHO 2022 classification of renal neoplasms (5th Edition):
Salient updates. Cureus. 16:e584702024.PubMed/NCBI
|
|
7
|
Didwaniya N, Edmonds RJ, Fang X,
Silberstein PT and Subbiah S: Survival outcomes in metastatic renal
carcinoma based on histological subtypes: SEER database analysis. J
Clin Oncol. 29:381. 2011. View Article : Google Scholar
|
|
8
|
Morais C, Gobe G, Johnson DW and Healy H:
Inhibition of nuclear factor kappa B transcription activity drives
a synergistic effect of pyrrolidine dithiocarbamate and cisplatin
for treatment of renal cell carcinoma. Apoptosis. 15:412–425. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Toth C, Funke S, Nitsche V, Liverts A,
Zlachevska V, Gasis M, Wiek C, Hanenberg H, Mahotka C, Schirmacher
P and Heikaus S: The role of apoptosis repressor with a CARD domain
(ARC) in the therapeutic resistance of renal cell carcinoma (RCC):
The crucial role of ARC in the inhibition of extrinsic and
intrinsic apoptotic signalling. Cell Commun Signal. 15:162017.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang WZ, Zhou H and Yan Y: XIAP underlies
apoptosis resistance of renal cell carcinoma cells. Mol Med Rep.
17:125–130. 2018.PubMed/NCBI
|
|
11
|
Wang L, Fu B, Hou DY, Lv YL, Yang G, Li C,
Shen JC, Kong B, Zheng LB, Qiu Y, et al: PKM2 allosteric converter:
A self-assembly peptide for suppressing renal cell carcinoma and
sensitizing chemotherapy. Biomaterials. 296:1220602023. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Diamond E, Molina AM, Carbonaro M, Akhtar
NH, Giannakakou P, Tagawa ST and Nanus DM: Cytotoxic chemotherapy
in the treatment of advanced renal cell carcinoma in the era of
targeted therapy. Crit Rev Oncol Hematol. 96:518–526. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Saliby RM, Saad E, Kashima S, Schoenfeld
DA and Braun DA: Update on biomarkers in renal cell carcinoma. Am
Soc Clin Oncol Educ Book. 44:e4307342024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lam JS, Pantuck AJ, Belldegrun AS and
Figlin RA: Protein expression profiles in renal cell carcinoma:
Staging, prognosis, and patient selection for clinical trials. Clin
Cancer Res. 13((2 Pt 2)): 703s–708s. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lee JN, Chun SY, Ha YS, Choi KH, Yoon GS,
Kim HT, Kim TH, Yoo ES, Kim BW and Kwon TG: Target molecule
expression profiles in metastatic renal cell carcinoma: Development
of individual targeted therapy. Tissue Eng Regen Med. 13:416–427.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patard JJ, Leray E, Rioux-Leclercq N,
Cindolo L, Ficarra V, Zisman A, De La Taille A, Tostain J, Artibani
W, Abbou CC, et al: Prognostic value of histologic subtypes in
renal cell carcinoma: A multicenter experience. J Clin Oncol.
23:2763–2771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Heng DY, Xie W, Regan MM, Harshman LC,
Bjarnason GA, Vaishampayan UN, Mackenzie M, Wood L, Donskov F, Tan
MH, et al: External validation and comparison with other models of
the International Metastatic Renal-Cell Carcinoma Database
Consortium prognostic model: A population-based study. Lancet
Oncol. 14:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kattan MW, Reuter V, Motzer RJ, Katz J and
Russo P: A Postoperative prognostic nomogram for renal cell
carcinoma. J Urol. 166:63–67. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
Renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Motzer R, Alekseev B, Rha SY, Porta C, Eto
M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ,
et al: Lenvatinib plus pembrolizumab or everolimus for advanced
renal cell carcinoma. N Engl J Med. 384:1289–1300. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
Renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rini BI, Powles T, Atkins MB, Escudier B,
McDermott DF, Suarez C, Bracarda S, Stadler WM, Donskov F, Lee JL,
et al: Atezolizumab plus bevacizumab versus sunitinib in patients
with previously untreated metastatic renal cell carcinoma
(IMmotion151): A multicentre, open-label, phase 3, randomised
controlled trial. The Lancet. 393:2404–2415. 2019. View Article : Google Scholar
|
|
26
|
Vogelzang NJ, Olsen MR, McFarlane JJ,
Arrowsmith E, Bauer TM, Jain RK, Somer B, Lam ET, Kochenderfer MD,
Molina A, et al: Safety and efficacy of nivolumab in patients with
advanced Non-clear cell renal cell carcinoma: Results from the
Phase IIIb/IV CheckMate 374 study. Clin Genitourin Cancer.
18:461–468.e3. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tykodi SS, Gordan LN, Alter RS, Arrowsmith
E, Harrison MR, Percent I, Singal R, Van Veldhuizen P, George DJ,
Hutson T, et al: Safety and efficacy of nivolumab plus ipilimumab
in patients with advanced non-clear cell renal cell carcinoma:
Results from the phase 3b/4 CheckMate 920 trial. J Immunother
Cancer. 10:e0038442022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pal SK, Albiges L, Tomczak P, Suárez C,
Voss MH, de Velasco G, Chahoud J, Mochalova A, Procopio G,
Mahammedi H, et al: Atezolizumab plus cabozantinib versus
cabozantinib monotherapy for patients with renal cell carcinoma
after progression with previous immune checkpoint inhibitor
treatment (CONTACT-03): A multicentre, randomised, Open-label,
phase 3 trial. The Lancet. 402:185–195. 2023. View Article : Google Scholar
|
|
29
|
Choueiri TK, Powles T, Burotto M, Escudier
B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U,
Shah AY, et al: Nivolumab plus cabozantinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 384:829–841. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Choueiri TK, Tomczak P, Park SH, Venugopal
B, Ferguson T, Chang YH, Hajek J, Symeonides SN, Lee JL, Sarwar N,
et al: Adjuvant pembrolizumab after nephrectomy in renal-cell
carcinoma. N Engl J Med. 385:683–694. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Monjaras-Avila CU, Lorenzo-Leal AC,
Luque-Badillo AC, D'Costa N, Chavez-Muñoz C and Bach H: The tumor
immune microenvironment in clear cell renal cell carcinoma. Int J
Mol Sci. 24:79462023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Karras P, Black JRM, McGranahan N and
Marine JC: Decoding the interplay between genetic and Non-genetic
drivers of metastasis. Nature. 629:543–554. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ucche S and Hayakawa Y: Immunological
aspects of cancer cell metabolism. Int J Mol Sci. 25:52882024.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bucciol G, Delafontaine S, Meyts I and
Poli C: Inborn errors of immunity: A field without frontiers.
Immunol Rev. 322:15–27. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kramer G, Blair T, Bambina S, Kaur AP,
Alice A, Baird J, Friedman D, Dowdell AK, Tomura M, Grassberger C,
et al: Fluorescence tracking demonstrates T cell recirculation is
transiently impaired by radiation therapy to the tumor. Sci Rep.
14:119092024. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tan D, Miao D, Zhao C, Shi J, Lv Q, Xiong
Z, Yang H and Zhang X: Comprehensive analyses of A
12-metabolism-associated gene signature and its connection with
tumor metastases in clear cell renal cell carcinoma. BMC Cancer.
23:2642023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu Y and Li X: Senescence gene expression
in clear cell renal cell carcinoma: Role of tumor immune
microenvironment and senescence-associated survival prediction.
Medicine (Baltimore). 102:e352222023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang Q, Lin B, Chen H, Ye Y, Huang Y,
Chen Z and Li J: Lipid Metabolism-related gene expression in the
immune microenvironment predicts prognostic outcomes in renal cell
carcinoma. Front Immunol. 14:13242052023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bahadoram S, Davoodi M, Hassanzadeh S,
Bahadoram M, Barahman M and Mafakher L: Renal cell carcinoma: An
overview of the epidemiology, diagnosis, and treatment. G Ital
Nefrol. 39:2022–vol3. 2022.PubMed/NCBI
|
|
40
|
Mickisch G, Bier H, Bergler W, Bak M,
Tschada R and Alken P: P-170 glycoprotein, glutathione and
associated enzymes in relation to chemoresistance of primary human
renal cell carcinomas. Urol Int. 45:170–176. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Guo Y, Schoell MC and Freeman RS: The von
Hippel-lindau protein sensitizes renal carcinoma cells to apoptotic
stimuli through stabilization of BIMEL. Oncogene. 28:18642009.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Büscheck F, Fraune C, Simon R, Kluth M,
Hube-Magg C, Möller-Koop C, Sarper I, Ketterer K, Henke T,
Eichelberg C, et al: Prevalence and clinical significance of VHL
mutations and 3p25 deletions in renal tumor subtypes. Oncotarget.
11:237–249. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ascierto ML, McMiller TL, Berger AE,
Danilova L, Anders RA, Netto GJ, Xu H, Pritchard TS, Fan J, Cheadle
C, et al: The intratumoral balance between metabolic and
immunologic gene expression is associated with Anti-PD-1 response
in patients with renal cell carcinoma. Cancer Immunol Res.
4:726–733. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rooney MS, Shukla SA, Wu CJ, Getz G and
Hacohen N: Molecular and genetic properties of tumors associated
with local immune cytolytic activity. Cell. 160:48–61. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Möller K, Fraune C, Blessin NC, Lennartz
M, Kluth M, Hube-Magg C, Lindhorst L, Dahlem R, Fisch M, Eichenauer
T, et al: Tumor cell PD-L1 expression is a strong predictor of
unfavorable prognosis in immune checkpoint Therapy-naive clear cell
renal cell cancer. Int Urol Nephrol. 53:2493–2503. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kawashima A, Kanazawa T, Kidani Y, Yoshida
T, Hirata M, Nishida K, Nojima S, Yamamoto Y, Kato T, Hatano K, et
al: Tumour grade significantly correlates with total dysfunction of
tumour Tissue-infiltrating lymphocytes in renal cell carcinoma. Sci
Rep. 10:62202020. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang Y, Yin C, Geng L and Cai W: Immune
infiltration landscape in clear cell renal cell carcinoma
implications. Front Oncol. 10:4916212021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sabrina S, Takeda Y, Kato T, Naito S, Ito
H, Takai Y, Ushijima M, Narisawa T, Kanno H, Sakurai T, et al:
Initial myeloid cell status is associated with clinical outcomes of
renal cell carcinoma. Biomedicines. 11:12962023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu B, Chen X, Zhan Y, Wu B and Pan S:
Identification of a gene signature for renal cell
Carcinoma-associated fibroblasts mediating cancer progression and
affecting prognosis. Front Cell Dev Biol. 8:6046272021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Zhang Y, Chen X, Fu Q, Wang F, Zhou X,
Xiang J, He N, Hu Z and Jin X: Comprehensive analysis of pyroptosis
regulators and tumor immune microenvironment in clear cell renal
cell carcinoma. Cancer Cell Int. 21:6672021. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ballesteros PÁ, Chamorro J, Román-Gil MS,
Pozas J, Gómez Dos Santos V, Granados ÁR, Grande E, Alonso-Gordoa T
and Molina-Cerrillo J: Molecular mechanisms of resistance to
immunotherapy and antiangiogenic treatments in clear cell renal
cell carcinoma. Cancers. 13:59812021. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Derosa L, Hellmann MD, Spaziano M,
Halpenny D, Fidelle M, Rizvi H, Long N, Plodkowski AJ, Arbour KC,
Chaft JE, et al: Negative association of antibiotics on clinical
activity of immune checkpoint inhibitors in patients with advanced
renal cell and Non-small-cell lung cancer. Ann Oncol. 29:1437–1444.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Routy B, Le Chatelier E, Derosa L, Duong
CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C,
Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based
immunotherapy against epithelial tumors. Science. 359:91–97. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Xing Y and Hogquist KA: T-cell tolerance:
Central and peripheral. Cold Spring Harb Perspect Biol.
4:a0069572012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Braun DA, Street K, Burke KP, Cookmeyer
DL, Denize T, Pedersen CB, Gohil SH, Schindler N, Pomerance L,
Hirsch L, et al: Progressive immune dysfunction with advancing
disease stage in renal cell carcinoma. Cancer Cell. 39:632–648.e8.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
McKay RR, Bossé D, Xie W, Wankowicz SAM,
Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, et
al: The clinical activity of PD-1/PD-L1 inhibitors in metastatic
non-clear cell renal cell carcinoma. Cancer Immunol Res. 6:758–765.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Pichler R, Siska PJ, Tymoszuk P, Martowicz
A, Untergasser G, Mayr R, Weber F, Seeber A, Kocher F, Barth DA, et
al: A chemokine network of T cell exhaustion and metabolic
reprogramming in renal cell carcinoma. Front Immunol.
14:10951952023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wang DY, Salem JE, Cohen JV, Chandra S,
Menzer C, Ye F, Zhao S, Das S, Beckermann KE, Ha L, et al: Fatal
toxic effects associated with immune checkpoint inhibitors. JAMA
Oncol. 4:1721–1728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Lin E, Liu X, Liu Y, Zhang Z, Xie L, Tian
K, Liu J and Yu Y: Roles of the dynamic tumor immune
microenvironment in the individualized treatment of advanced clear
cell renal cell carcinoma. Front Immunol. 12:6533582021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ishihara H, Takagi T, Kondo T, Fukuda H,
Tachibana H, Yoshida K, Iizuka J, Okumi M, Ishida H and Tanabe K:
Predictive impact of an early change in serum C-reactive protein
levels in nivolumab therapy for metastatic renal cell carcinoma.
Urol Oncol Semin Orig Investig. 38:526–532. 2020.
|
|
61
|
Noguchi G, Nakaigawa N, Umemoto S,
Kobayashi K, Shibata Y, Tsutsumi S, Yasui M, Ohtake S, Suzuki T,
Osaka K, et al: C-reactive protein at 1 month after treatment of
nivolumab as a predictive marker of efficacy in advanced renal cell
carcinoma. Cancer Chemother Pharmacol. 86:75–85. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yano Y, Ohno T, Komura K, Fukuokaya W,
Uchimoto T, Adachi T, Hirasawa Y, Hashimoto T, Yoshizawa A,
Yamazaki S, et al: Serum C-reactive protein level predicts overall
survival for clear cell and Non-clear cell renal cell carcinoma
treated with ipilimumab plus nivolumab. Cancers. 14:56592022.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tomita Y, Larkin J, Venugopal B, Haanen J,
Kanayama H, Eto M, Grimm MO, Fujii Y, Umeyama Y, Huang B, et al:
Association of C-reactive protein with efficacy of avelumab plus
axitinib in advanced renal cell carcinoma: Long-term follow-up
results from JAVELIN renal 101. ESMO Open. 7:1005642022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kim JH, Kim GH, Ryu YM, Kim SY, Kim HD,
Yoon SK, Cho YM and Lee JL: Clinical implications of the tumor
microenvironment using multiplexed immunohistochemistry in patients
with advanced or metastatic renal cell carcinoma treated with
nivolumab plus ipilimumab. Front Oncol. 12:9695692022. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Sammarco E, Rossetti M, Salfi A, Bonato A,
Viacava P, Masi G, Galli L and Faviana P: Tumor microenvironment
and clinical efficacy of first line Immunotherapy-based
combinations in metastatic renal cell carcinoma. Med Oncol.
41:1502024. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kazama A, Bilim V, Tasaki M, Anraku T,
Kuroki H, Shirono Y, Murata M, Hiruma K and Tomita Y:
Tumor-infiltrating immune cell status predicts successful response
to immune checkpoint inhibitors in renal cell carcinoma. Sci Rep.
12:203862022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Herrmann T, Ginzac A, Molnar I, Bailly S,
Durando X and Mahammedi H: Eosinophil counts as a relevant
prognostic marker for response to nivolumab in the management of
renal cell carcinoma: A retrospective study. Cancer Med.
10:6705–6713. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Atkins MB, Jegede OA, Haas NB, McDermott
DF, Bilen MA, Stein M, Sosman JA, Alter R, Plimack ER, Ornstein M,
et al: Phase II study of nivolumab and salvage Nivolumab/Ipilimumab
in Treatment-naive patients with advanced clear cell renal cell
carcinoma (HCRN GU16-260-Cohort A). J Clin Oncol. 40:2913–2923.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Motzer RJ, Choueiri TK, McDermott DF,
Powles T, Vano YA, Gupta S, Yao J, Han C, Ammar R,
Papillon-Cavanagh S, et al: Biomarker analysis from CheckMate 214:
Nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.
J Immunother Cancer. 10:e0043162022. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Brown LC, Zhu J, Desai K, Kinsey E, Kao C,
Lee YH, Pabla S, Labriola MK, Tran J, Dragnev KH, et al: Evaluation
of tumor microenvironment and biomarkers of immune checkpoint
inhibitor response in metastatic renal cell carcinoma. J Immunother
Cancer. 10:e0052492022. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Kato R, Jinnouchi N, Tuyukubo T, Ikarashi
D, Matsuura T, Maekawa S, Kato Y, Kanehira M, Takata R, Ishida K
and Obara W: TIM3 expression on tumor cells predicts response to
anti-PD-1 therapy for renal cancer. Transl Oncol. 14:1009182020.
View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Koh Y, Nakano K, Katayama K, Yamamichi G,
Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Yamamoto Y, Kato T,
et al: Early dynamics of circulating tumor DNA predict clinical
response to immune checkpoint inhibitors in metastatic renal cell
carcinoma. Int J Urol. 29:462–469. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Incorvaia L, Fanale D, Badalamenti G,
Brando C, Bono M, De Luca I, Algeri L, Bonasera A, Corsini LR,
Scurria S, et al: A ‘Lymphocyte MicroRNA Signature’ as predictive
biomarker of immunotherapy response and plasma PD-1/PD-L1
expression levels in patients with metastatic renal cell carcinoma:
Pointing towards epigenetic reprogramming. Cancers. 12:33962020.
View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Pan Q, Liu R, Zhang X, Cai L, Li Y, Dong
P, Gao J, Liu Y and He L: CXCL14 as a potential marker for
immunotherapy response prediction in renal cell carcinoma. Ther Adv
Med Oncol. 15:175883592312179662023. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Pabla S, Seager RJ, Van Roey E, Gao S,
Hoefer C, Nesline MK, DePietro P, Burgher B, Andreas J, Giamo V, et
al: Integration of tumor inflammation, cell proliferation, and
traditional biomarkers improves prediction of immunotherapy
resistance and response. Biomark Res. 9:562021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Schalper KA, Carleton M, Zhou M, Chen T,
Feng Y, Huang SP, Walsh AM, Baxi V, Pandya D, Baradet T, et al:
Elevated serum interleukin-8 is associated with enhanced intratumor
neutrophils and reduced clinical benefit of immune-checkpoint
inhibitors. Nat Med. 26:688–692. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Ivanova E, Asadullina D, Rakhimov R,
Izmailov A, Izmailov A, Gilyazova G, Galimov S, Pavlov V,
Khusnutdinova E and Gilyazova I: Exosomal miRNA-146a is
downregulated in clear cell renal cell carcinoma patients with
severe immune-related adverse events. Noncoding RNA Res. 7:159–163.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Petitprez F, Ayadi M, de Reyniès A,
Fridman WH, Sautès-Fridman C and Job S: Review of prognostic
expression markers for clear cell renal cell carcinoma. Front
Oncol. 11:6430652021. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Lee A, Lee HJ, Huang HH, Tay KJ, Lee LS,
Sim SPA, Ho SSH, Yuen SPJ and Chen K: Prognostic significance of
inflammation-associated blood cell markers in nonmetastatic clear
cell renal cell carcinoma. Clin Genitourin Cancer. 18:304–313.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Teishima J, Inoue S, Hayashi T and
Matsubara A: Current status of prognostic factors in patients with
metastatic renal cell carcinoma. Int J Urol. 26:608–617. 2019.
View Article : Google Scholar : PubMed/NCBI
|
